Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by, and welcome to the Innate Pharma First Half twenty twenty five Business Update and Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I'd now like to turn the call over to Stephanie Cornyn, Vice President, Investor Relations and Communications. You may begin. Good morning and good afternoon everyone. Thank you for joining us for Innate Pharma H1 twenty twenty five business update and financial results conference call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I'd like to remind everyone that today's presentation includes forward looking statements based on current expectation. These statements involve risks and uncertainties that could cause actual results to differ materially. I briefly cover today's agenda. Our CEO, Jonathan Dickinson, will discuss our strategic overview, fast forward, and commercial opportunity. Our CEO, Yanis Morrell, will provide an update on the scientific differentiation of our lead ADC. He will then hand over to our CMO, Sonia Coratino, who will present clinical pipeline updates on IPH4502, lacutamab, and monalizumab. Afterward, our CFO, Frederic Lombard, will review the financial. Then Jonathan will return with closing remarks and will open the call for Q and A. With that, I'll now hand it over to Jonathan. Thank you, Stephanie, and good morning to those joining from The US and good afternoon to our participants in Europe. Moving to slide five, Innate Pharma's foundation is in leveraging our deep scientific expertise to advance life enhancing cancer therapies. Through our years of pioneering work in antibody en...